Results 1 to 10 of about 290,727 (340)
Outcomes and physiologic responses associated with ketamine administration after traumatic brain injury in the United States and Canada: a retrospective analysis [PDF]
Journal of Trauma and Injury, 2023 Purpose Ketamine has historically been contraindicated in traumatic brain injury (TBI) due to concern for raising intracranial pressure. However, it is increasingly being used in TBI due to the favorable respiratory and hemodynamic properties.
Austin J. Peters +4 more
doaj +1 more source
Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses
Frontiers in Psychiatry, 2023 Ketamine-assisted psychotherapy is a promising new treatment for a variety of mental disorders of adolescence. There is currently an adolescent mental health crisis, with a high prevalence of disorders, diagnostic complexity, and many adolescents failing
Philip E. Wolfson +7 more
doaj +1 more source
Heliyon, 2023 Co-occurrence of posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI) symptoms are particularly prevalent in the special operations forces' community, along with other related conditions (e.g., endocrine dysregulation, sleep disorders ...
Eugene Lipov +3 more
doaj +1 more source
International Review of Psychiatry, 2021 Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-Methyl-D-Aspartate (NMDA) receptor antagonist, has emerged as a novel therapy for treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects within hours of administration.
James M. Stone +3 more
openaire +3 more sources
Frontiers in Psychiatry, 2021 Background: Craving is considered a hallmark of substance use disorder and is one of the criteria of substance use disorder. The Desires for Drug Questionnaire (DDQ) is a widely used questionnaire to assess craving for heroin. This study aimed to examine
Peng-Wei Wang +10 more
doaj +1 more source
BJPsych Open, 2023 Background The evidence base for racemic ketamine treatment for treatment-resistant major depressive disorder (TRD) continues to expand, but there are major challenges translating this evidence base into routine clinical care.
Ben Beaglehole +3 more
doaj +1 more source
BMJ, 1996 EDITOR,—There is increasing concern over the toxic1 and neurodegenerative2 effects of ecstasy, and further research is clearly required. Potential hazards can also, however, arise through use of tablets sold as ecstasy that contain substances other than ecstasy, such as ketamine. Ketamine is an anaesthetic agent with a rapid action that has medical and
Shewan, David +2 more
openaire +3 more sources
NMDA Receptor Glycine Binding Site Modulators for Prevention and Treatment of Ketamine Use Disorder
Pharmaceuticals, 2023 Ketamine offers a fast-acting approach to relieving treatment-resistant depression, but its abuse potential is an issue of concern. As ketamine is a noncompetitive N-methyl-D-aspartate receptor (NMDAR) ion channel blocker, modulation of NMDAR might be an
Yu-Chin Hsiao +3 more
doaj +1 more source
Frontiers in Psychiatry, 2021 Ketamine is a glutamate N-methyl D-aspartate receptor antagonist and an anaesthetic agent that has been effectively used to treat depression. However, ketamine has also been increasingly used for recreational purposes.
Linying Liu +8 more
doaj +1 more source